Protagonist Therapeutics

#Hematology #Rare Blood Disorders #Autoimmune Diseases

A biopharmaceutical company focused on discovering and developing peptide-based novel therapeutics for hematology and hematology-related conditions.

Company Info

Sector:RNA, Peptide & Gene Therapy

Headquarters:Newark, California, USA

Founded:2006

Website:www.protagonist-inc.com/

Upcoming Milestones & Key Dates

2026-Q4

Commercial

Rusfertide commercial launch update

2027-H1

Clinical

PN-943 Phase 2 topline data

Clinical Development Pipeline

Rusfertide

Target: Hepcidin mimetic

Polycythemia Vera

Preclinical

Phase 1

Phase 2

Phase 3

Approved

PN-943

Target: Alpha-4-beta-7 integrin

Ulcerative Colitis

Preclinical

Phase 1

Phase 2

Phase 3

Approved

PN-235

Target: IL-23 receptor antagonist

Various Autoimmune

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

No recent news updates available for this company.

Leadership Team

Dinesh V. Patel

President and Chief Executive Officer

Hari Pujar

Chief Operating Officer

Suneel Gupta

Chief Medical Officer

Careers & Job Openings

See all open roles

Apply Now →